Hims & Hers Health, Inc. $HIMS Shares Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC raised its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 427.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 33,582 shares of the company’s stock after purchasing an additional 27,211 shares during the period. Hsbc Holdings PLC’s holdings in Hims & Hers Health were worth $1,090,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. boosted its position in Hims & Hers Health by 13.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 41,088 shares of the company’s stock worth $1,334,000 after acquiring an additional 4,980 shares during the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in Hims & Hers Health during the fourth quarter valued at about $80,000. SHP Wealth Management purchased a new stake in shares of Hims & Hers Health during the 4th quarter worth about $106,000. Caitong International Asset Management Co. Ltd grew its stake in Hims & Hers Health by 413.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 17,228 shares of the company’s stock worth $559,000 after buying an additional 13,873 shares during the period. Finally, MidFirst Bank purchased a new stake in Hims & Hers Health during the 4th quarter worth $146,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on HIMS shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $25.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, May 5th. BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Leerink Partners increased their target price on shares of Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a report on Monday, March 16th. Weiss Ratings cut shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a report on Tuesday, May 12th. Finally, Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $30.70.

Hims & Hers Health Stock Up 0.0%

HIMS stock opened at $34.40 on Tuesday. The stock has a market cap of $7.96 billion, a PE ratio of -382.19, a price-to-earnings-growth ratio of 96.75 and a beta of 2.35. The firm’s 50-day simple moving average is $29.51 and its 200 day simple moving average is $26.33. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. During the same period in the previous year, the firm earned $0.20 earnings per share. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.03 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Patrick Harrison Carroll sold 23,726 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $35.00, for a total value of $830,410.00. Following the sale, the insider directly owned 181,861 shares in the company, valued at $6,365,135. This trade represents a 11.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $25.90, for a total value of $956,279.80. Following the sale, the chief financial officer directly owned 281,867 shares in the company, valued at $7,300,355.30. The trade was a 11.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 167,161 shares of company stock valued at $5,041,152. 11.76% of the stock is currently owned by insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.